Description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.{53462,53459,53461,55257,55258} The SARS-CoV-2 genome encodes four structural proteins: surface glycoprotein, envelope, membrane, and nucleocapsid.{53459,53462} The surface glycoprotein, also known as the spike glycoprotein, is located on the outer envelope of the virion and binds to the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), which acts as the functional receptor for SARS-CoV-2 and facilitates virus cell entry.{53462} SARS-CoV-2 infection results in the production of neutralizing antibodies, which bind to the SARS-CoV-2 spike glycoprotein receptor binding domain and prevent further viral entry and infection, starting approximately 4-10 days after symptom onset.{55337,55338} Plasma levels of SARS-CoV-2 spike glycoprotein-specific IgG antibodies increase for at least four weeks following symptom onset.{55337,55339} SARS-CoV-2 plasma antibody levels begin to decrease 2-3 months post-infection in both symptomatic and asymptomatic individuals, disappearing completely in some asymptomatic individuals.{55340} This product contains pre-pandemic human serum negative for SARS-CoV-2 neutralizing antibodies.
Synonyms: COVID-19 Neutralizing Antibody-Negative Pre-pandemic Human Serum
Immunogen:
Formulation: 50 µl human serum
Isotype:
Applications:
Origin:
Stability: 730 days
Application|ELISA||Product Type||Research Area|Immunology & Inflammation|Pulmonary Diseases||Research Area|Infectious Disease|Viral Diseases|Coronaviruses
